File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Immunotherapy for EBV-associated nasopharyngeal carcinoma

TitleImmunotherapy for EBV-associated nasopharyngeal carcinoma
Authors
KeywordsNasopharyngeal carcinoma
Immunotherapy
EBV
Issue Date2018
Citation
Critical Reviews in Oncogenesis, 2018, v. 23, n. 3-4, p. 219-234 How to Cite?
Abstract© 2018 Begell House, Inc. Epstein-Barr virus (EBV)-associated nasopharyngeal carcinoma (NPC) is one of the most common head and neck malignancies in southern China and Southeast Asia. Unfortunately, 70% of NPC patients have locally advanced disease at the first diagnosis. Radiotherapy alone and concurrent chemoradiotherapy are important treatment approaches for NPC, but they have a limited effect on patients with locally advanced or distantly metastatic disease.1–5 Nevertheless, the unique immune environment of the EBV-associated NPC provides rational targets for immunotherapy. Diverse types of immunotherapies are actively being studied, including adoptive immunotherapy, therapeutic vaccines, immune checkpoint inhibitors, lytic-induction therapy, and viral immunotherapy. Specifically, adoptive immunotherapy with lymphocyte infusion was well tolerated and effective in 71.4% of patients combined with first-line chemotherapy. Several therapeutic vaccines and PD-1/PD-L1 pathway checkpoint inhibitors have shown promising clinic outcomes at phase I/II clinical trials. Moreover, EBV-lytic inducing therapy and viral immunotherapy for NPC are also being investigated. In this review, we summarized the current status, advantages, and disadvantages of each immunotherapy for EBV-associated NPC, which may shed light on developing safer and more effective treatment modalities in the future.
Persistent Identifierhttp://hdl.handle.net/10722/286036
ISSN
2023 SCImago Journal Rankings: 0.319

 

DC FieldValueLanguage
dc.contributor.authorHong, Mengying-
dc.contributor.authorTang, Kejun-
dc.contributor.authorQian, Jing-
dc.contributor.authorDeng, Hongyu-
dc.contributor.authorZeng, Musheng-
dc.contributor.authorZheng, Shu-
dc.contributor.authorDing, Kefeng-
dc.contributor.authorDu, Yushen-
dc.contributor.authorSun, Ren-
dc.date.accessioned2020-08-30T12:57:22Z-
dc.date.available2020-08-30T12:57:22Z-
dc.date.issued2018-
dc.identifier.citationCritical Reviews in Oncogenesis, 2018, v. 23, n. 3-4, p. 219-234-
dc.identifier.issn0893-9675-
dc.identifier.urihttp://hdl.handle.net/10722/286036-
dc.description.abstract© 2018 Begell House, Inc. Epstein-Barr virus (EBV)-associated nasopharyngeal carcinoma (NPC) is one of the most common head and neck malignancies in southern China and Southeast Asia. Unfortunately, 70% of NPC patients have locally advanced disease at the first diagnosis. Radiotherapy alone and concurrent chemoradiotherapy are important treatment approaches for NPC, but they have a limited effect on patients with locally advanced or distantly metastatic disease.1–5 Nevertheless, the unique immune environment of the EBV-associated NPC provides rational targets for immunotherapy. Diverse types of immunotherapies are actively being studied, including adoptive immunotherapy, therapeutic vaccines, immune checkpoint inhibitors, lytic-induction therapy, and viral immunotherapy. Specifically, adoptive immunotherapy with lymphocyte infusion was well tolerated and effective in 71.4% of patients combined with first-line chemotherapy. Several therapeutic vaccines and PD-1/PD-L1 pathway checkpoint inhibitors have shown promising clinic outcomes at phase I/II clinical trials. Moreover, EBV-lytic inducing therapy and viral immunotherapy for NPC are also being investigated. In this review, we summarized the current status, advantages, and disadvantages of each immunotherapy for EBV-associated NPC, which may shed light on developing safer and more effective treatment modalities in the future.-
dc.languageeng-
dc.relation.ispartofCritical Reviews in Oncogenesis-
dc.subjectNasopharyngeal carcinoma-
dc.subjectImmunotherapy-
dc.subjectEBV-
dc.titleImmunotherapy for EBV-associated nasopharyngeal carcinoma-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1615/CritRevOncog.2018027528-
dc.identifier.pmid30311576-
dc.identifier.scopuseid_2-s2.0-85054777381-
dc.identifier.volume23-
dc.identifier.issue3-4-
dc.identifier.spage219-
dc.identifier.epage234-
dc.identifier.eissn2162-6448-
dc.identifier.issnl0893-9675-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats